{"symbol":"REGN","fiscalQuarter":"Q2-2024","reportDate":"2024-08-01","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2024","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.29%","keyNumbers":[{"metric":"EPS","actual":"$11.56","expected":"N/A","surprise":"+29.47%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on innovation and delivering value to patients."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific revenue figures or future guidance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, exceeding expectations by nearly 30%, led to a positive stock reaction, with shares rising 1.29%. The lack of revenue data and guidance leaves some uncertainty, but the management's optimistic tone suggests confidence in future performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2024 earnings: EPS beat by 29.47%. Stock up 1.29%. Full breakdown."}}